Ginkgo biloba and acetazolamide for acute mountain sickness: Exclusion of high risk, low status groups perpetuates discrimination and inequalitiesBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7458.171-b (Published 15 July 2004) Cite this as: BMJ 2004;329:171
- Jean Adams (firstname.lastname@example.org), research fellow
- School of Population and Health Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH
EDITOR—Gertsch et al report the results of a randomised controlled trial of ginkgo biloba and acetazolamide for acute mountain sickness in trekkers in the Everest region of Nepal.1 However, it is …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial